Depot Extracts for Venom Immunotherapy: A Delphi Consensus on Safety and Efficacy

Valerio Pravettoni; Matteo Martini; Donatella Bignardi; Alessandro Buonomo; M. Cilia; Domenico Gargano; Marina Mauro; F Murzilli; Luisa Ricciardi; M. Beatrice Bilò; the Allergy Venom Expert group

doi:10.1111/cea.70278

March 10, 2026Clinical & Experimental Allergy

Depot Extracts for Venom Immunotherapy: A Delphi Consensus on Safety and Efficacy

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess the safety and efficacy of Depot Venom Immunotherapy (dVIT).
Consensus reached through a Delphi method involving experts in immunotherapy.
Comparison of dVIT safety with aqueous venom immunotherapy protocols.
Evaluation of immunological enhancements with dVIT.
dVIT safety is comparable to aqueous venom immunotherapy.
Immunological specific enhancements were identified, indicating potential benefits.

Implication

Delphi consensus evaluates safety and efficacy of depot venom immunotherapy, indicating promising outcomes.

Abstract

Summary A Delphi consensus, funded by an immunotherapy manufacturer, was reached on Depot Venom Immunotherapy (dVIT). dVIT safety is similar to aqueous VIT (rush and ultra‐rush protocols), with immunological specific enhancements.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pravettoni et al. (2026) studied this question.

synapsesocial.com/papers/69b3ac9002a1e69014cce6ca https://doi.org/10.1111/cea.70278

View at Publisher

Ask AI

Bookmark

Share

Depot Extracts for Venom Immunotherapy: A Delphi Consensus on Safety and Efficacy

Key Points

Implication

Abstract

Discussion

Cite This Study

Depot Extracts for Venom Immunotherapy: A Delphi Consensus on Safety and Efficacy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading